GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » MedCap AB (OSTO:MCAP) » Definitions » Altman Z-Score

MedCap AB (OSTO:MCAP) Altman Z-Score : 6.06 (As of Apr. 08, 2025)


View and export this data going back to 2004. Start your Free Trial

What is MedCap AB Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Good Sign:

Altman Z-score of 6.2 is strong.

MedCap AB has a Altman Z-Score of 6.06, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for MedCap AB's Altman Z-Score or its related term are showing as below:

OSTO:MCAP' s Altman Z-Score Range Over the Past 10 Years
Min: 2.61   Med: 4.32   Max: 9.41
Current: 6.2

During the past 13 years, MedCap AB's highest Altman Z-Score was 9.41. The lowest was 2.61. And the median was 4.32.


MedCap AB Altman Z-Score Historical Data

The historical data trend for MedCap AB's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedCap AB Altman Z-Score Chart

MedCap AB Annual Data
Trend Apr15 Apr16 Apr17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Altman Z-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.71 5.05 5.30 6.94 9.41

MedCap AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.94 6.81 7.75 8.27 9.41

Competitive Comparison of MedCap AB's Altman Z-Score

For the Medical Devices subindustry, MedCap AB's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MedCap AB's Altman Z-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, MedCap AB's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where MedCap AB's Altman Z-Score falls into.


;
;

MedCap AB Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

MedCap AB's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.2943+1.4*0+3.3*0.1418+0.6*7.2116+1.0*0.9072
=6.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2024:
Total Assets was kr1,991 Mil.
Total Current Assets was kr917 Mil.
Total Current Liabilities was kr331 Mil.
Retained Earnings was kr0 Mil.
Pre-Tax Income was 52.7 + 64.9 + 72.4 + 71.6 = kr262 Mil.
Interest Expense was -6.3 + -4.3 + -5.8 + -4.3 = kr-21 Mil.
Revenue was 474.2 + 413 + 457.7 + 461.7 = kr1,807 Mil.
Market Cap (Today) was kr5,071 Mil.
Total Liabilities was kr703 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(917.4 - 331.4)/1991.4
=0.2943

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(261.6 - -20.7)/1991.4
=0.1418

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=5071.188/703.2
=7.2116

X5=Revenue/Total Assets
=1806.6/1991.4
=0.9072

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

MedCap AB has a Altman Z-Score of 6.06 indicating it is in Safe Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


MedCap AB  (OSTO:MCAP) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


MedCap AB Altman Z-Score Related Terms

Thank you for viewing the detailed overview of MedCap AB's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


MedCap AB Business Description

Traded in Other Exchanges
Address
Sundbybergsvagen 1, Solna, SWE, 171 73
MedCap AB acquires and develops profitable, market-leading niche companies in the Nordic life science industry. It is diversified into two business areas namely Medical technology and Specialist medicines. Medical Technology mainly develops and sells various medical technology products and services. Its Specialist medicines develop and sell medicines within the regulatory classes of registered, extemporaneous and licensed medicines.

MedCap AB Headlines

From GuruFocus

MCAP Inc. Expands ETF Division and Announces Senior Hire

By PRNewswire PRNewswire 10-19-2022

MCAP Inc. Reports Second Quarter 2022 EPS of $0.10 Per Share

By PRNewswire PRNewswire 08-04-2022

MCAP Inc. Reports First Quarter 2022 EPS of $0.15 Per Share

By PRNewswire PRNewswire 05-09-2022

MCAP Inc. Announces $0.05 Dividend Per Share

By PRNewswire 03-13-2024

MCAP Inc. Expands ETF Division and Announces Senior Hire

By PRNewswire PRNewswire 05-04-2022

Mango Capital, Inc. Announces Name Change and Reverse Split

By ACCESSWIRE ACCESSWIRE 11-03-2021

MCAP Inc. Reports First Quarter 2022 EPS of $0.15 Per Share

By PRNewswire PRNewswire 05-29-2022

MCAP Inc. Reports First Quarter 2022 EPS of $0.15 Per Share

By PRNewswire PRNewswire 06-18-2022